- Home
- DTSQ vs TCRX Comparison
DTSQ vs TCRX Comparison
Compare DTSQ & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTSQ
- TCRX
- Stock Information
- Founded
- DTSQ 2022
- TCRX 2018
- Country
- DTSQ United States
- TCRX United States
- Employees
- DTSQ N/A
- TCRX N/A
- Industry
- DTSQ
- TCRX Biotechnology: Pharmaceutical Preparations
- Sector
- DTSQ
- TCRX Health Care
- Exchange
- DTSQ NYSE
- TCRX Nasdaq
- Market Cap
- DTSQ 91.7M
- TCRX 82.1M
- IPO Year
- DTSQ 2024
- TCRX 2021
- Fundamental
- Price
- DTSQ $10.39
- TCRX $1.81
- Analyst Decision
- DTSQ
- TCRX Strong Buy
- Analyst Count
- DTSQ 0
- TCRX 6
- Target Price
- DTSQ N/A
- TCRX $9.50
- AVG Volume (30 Days)
- DTSQ 531.0
- TCRX 642.3K
- Earning Date
- DTSQ 01-01-0001
- TCRX 08-11-2025
- Dividend Yield
- DTSQ N/A
- TCRX N/A
- EPS Growth
- DTSQ N/A
- TCRX N/A
- EPS
- DTSQ 0.28
- TCRX N/A
- Revenue
- DTSQ N/A
- TCRX $4,421,000.00
- Revenue This Year
- DTSQ N/A
- TCRX $159.20
- Revenue Next Year
- DTSQ N/A
- TCRX N/A
- P/E Ratio
- DTSQ $37.07
- TCRX N/A
- Revenue Growth
- DTSQ N/A
- TCRX N/A
- 52 Week Low
- DTSQ $9.96
- TCRX $1.02
- 52 Week High
- DTSQ $10.49
- TCRX $7.89
- Technical
- Relative Strength Index (RSI)
- DTSQ N/A
- TCRX 62.32
- Support Level
- DTSQ N/A
- TCRX $1.45
- Resistance Level
- DTSQ N/A
- TCRX $1.90
- Average True Range (ATR)
- DTSQ 0.00
- TCRX 0.14
- MACD
- DTSQ 0.00
- TCRX 0.04
- Stochastic Oscillator
- DTSQ 0.00
- TCRX 82.00
About DTSQ DT CLOUD STAR ACQUISITION CORP
DT Cloud Star Acquisition Corp is a blank check company.
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.